Skip to content
Science
Our Science
Autoimmunity
P140
Type M & Diagnostic
Type 1 Diabetes
Kapiglucagon
Anti-infectives
BioAMB
BioCIN
Pipeline
Company
Mission
About Us
Our Team
ImmuPharma Biotech
Investors
Investors
AIM Rule 26 Information
Regulatory News
Corporate Governance
Board of Directors
Annual Reports
Advisers
Email Alert
Updates
Announcements
Interviews
In the Media
Contact
Major shareholding from Lanstead Capital via TR1
Sep 6, 2023
To view
click here
←
Previous:
Subscriptions to raise £1.35 million; Sharing Agreement; WRAP Retail Offer to raise up to £0.5 million • Related Party Transactions
Next:
Result of retail offer and Director shareholding
→